Skip to main content

BioAge Labs, Inc 10-Q for FY2026 Q3

BioAge Labs, Inc. (BIOA)

10-Q 2026-11-05 For: 2026-09-30
View Original
Added on November 05, 2026

About this 10-Q

BioAge Labs, Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

BioAge dosed first participants in QUELL-CV and QUELL-DME Phase 2 trials in June 2026 and September 2026. At September 30, 2026, it held $352.3 million in cash, cash equivalents, and marketable securities and expects funding through 2029. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$298K
down 85.5% from $2.05M a year earlier
Net loss
$33.5M
compared with a net loss of $20.17M a year earlier
Diluted EPS
-$0.73
compared with -$0.56 a year earlier